The $149M is gross, however they are selling for less than their investment, even though there is a gaap gain..
I think that AHT is undervalued right now. However in looking at gaap book value, almost half of the 8$ per share in equity is represented by preferred stock.
Interesting analysis. Thanks. I also tried to volunteer to aid in the posting. I now know that putting an email address in a post is not going to work.
The Checkpoint Immunotherapy Revolution by Walter Alexander gives an update "published 3/16" on immunotherapy. The article can be accessed at www.ncbi.nlm.nih.gov/pmc/articles/PMC4771089/
I just read an article about and interview with Dr. Sigal. It was written by Ben Fidler of Exome on 2/25/14. It provides a lot of insight into Dr. Sigal's career and what he hoped to do at that time.